• Health Care Professional Information
  • Contact
  • Sitemap
  • Bayer AG
  • Key Facts
    • Hypertension
    • Guidelines
    • Product Characteristics
    • Development milestones
  • Efficacy in monotherapy
    • BP lowering effect
    • High-risk hypertensive patients
    • Asian hypertensive populations
    • Safety and tolerability in monotherapy
  • Preferred in combination
    • Preferred combination partner
    • Preferred partner for RAS blockers
    • Safety and tolerability in combination therapy
    • Preferred in combination - Summary
  • Specific formulation
    • Unique GITS technology
    • Distinct PK/PD profile
    • Unique properties leading to 24h BP control
    • Generic differentiation
  • Guidelines
    • Europe
    • UK
    • USA
    • Canada
    • China
    • Korea
    • Taiwan
  • Patient Area
  • Menu
  • Search
  • Sitemap
  • Patient Area

This website contains information on Bayer Adalat (nifedipine). Here you can find Health Care Professional Information.
Last updated: 16.05.2018
G.MKT.GM.ADA.06.2018.0086

  • 2018 Bayer AG.
  • Privacy Statement
  • Imprint
  • General Conditions of Use
Menu Adalat

Home Professional

Key Facts

  • Hypertension
  • Guidelines
  • Product Characteristics
  • Development milestones

Efficacy in monotherapy

  • BP lowering effect
  • High-risk hypertensive patients
  • Asian hypertensive populations
  • Safety and tolerability in monotherapy

Preferred in combination

  • Preferred combination partner
  • Preferred partner for RAS blockers
  • Safety and tolerability in combination therapy
  • Preferred in combination - Summary

Specific formulation

  • Unique GITS technology
  • Distinct PK/PD profile
  • Unique properties leading to 24h BP control
  • Generic differentiation

Guidelines

  • Europe
  • UK
  • USA
  • Canada
  • China
  • Korea
  • Taiwan
  • Health Care Professional Information
  • Contact
  • Sitemap
  • Bayer AG
  • Newsletter